Breaking Down Beijing Tongrentang Co., Ltd Financial Health: Key Insights for Investors

Investors evaluating Beijing Tongrentang Co., Ltd (600085.SS) will want to weigh a mixed set of facts: in Q3 2025 revenue fell to CNY 3.54 billion (a 12.76% year‑over‑year decline) even as TTM revenue sits at CNY 18.09 billion (up 0.70% YoY) and 2024 annual revenue reached CNY 18.60 billion (up 4.12%); profitability shows pressure with Q3 2025 net profit attributable to shareholders of CNY 232.06 million (down 29.49% YoY) but a TTM net income of CNY 1.35 billion yielding a 7.48% net margin and operating margin of 18.00%; balance sheet and cash metrics include a market capitalization of CNY 45.88 billion, cash and equivalents of CNY 11.4 billion versus total debt of CNY 3.1 billion (net cash position), a current ratio of 3.45, quick ratio of 1.82, TTM free cash flow of CNY 1.1 billion and an interest coverage ratio of 17.15; valuation multiples to consider are a TTM P/E of 32.02, forward P/E of 25.08, P/S of 2.54 and EV/EBITDA of 16.81, while efficiency and returns include revenue per employee of ~CNY 1.01 million, ROE of 9.01% and ROIC of 5.64%; risks such as the Q3 revenue and profit declines and reliance on traditional Chinese medicine contrast with growth levers-minority biotech stake (estimated CNY 200 million incremental revenue over five years), projected 12% CAGR to 2026, and digital channel ambitions-so read on for a detailed chapter‑by‑chapter breakdown.

Beijing Tongrentang Co., Ltd (600085.SS) - Revenue Analysis

• Q3 2025 revenue: CNY 3.54 billion (-12.76% YoY), indicating short-term pressure on sales.
• Trailing twelve months (TTM) revenue: CNY 18.09 billion (+0.70% YoY), reflecting near-flat annualized sales.
• Full-year 2024 revenue: CNY 18.60 billion (+4.12% vs. 2023), showing modest year-over-year expansion in the prior year.
• Revenue per employee: ~CNY 1.01 million based on 17,883 employees - useful for productivity benchmarking.
• Price-to-sales (P/S) ratio: 2.54 - market valuation relative to sales indicating investor willingness to pay a premium.
• Market capitalization: CNY 45.88 billion - signals company scale within the pharmaceutical/TCM sector.

• Short-term: Q3 decline suggests seasonality, product mix shifts, or distribution/headwind issues requiring monitoring of next quarters.
• Medium-term: TTM and 2024 growth show resilience but limited momentum; management execution and new product ramps will be key to accelerate growth.
• Valuation: P/S of 2.54 combined with CNY 45.88 billion market cap implies investors price in steady franchise value; compare with peers for relative attractiveness.

Beijing Tongrentang Co., Ltd (600085.SS) - Profitability Metrics

Beijing Tongrentang Co., Ltd (600085.SS) reported profitability figures that show mixed momentum across margins and returns. Key headline metrics and their implications are summarized below.

• Q3 2025 net profit attributable to shareholders: CNY 232.06 million (down 29.49% YoY).
• Trailing twelve months (TTM) net income: CNY 1.35 billion; TTM revenue: CNY 18.09 billion; TTM net profit margin ≈ 7.48%.
• Operating margin: 18.00%, indicating relatively strong core operating efficiency versus the net margin.
• Return on Equity (ROE): 9.01% - moderate shareholder returns.
• Return on Assets (ROA): 4.51% - moderate asset utilization.
• Return on Invested Capital (ROIC): 5.64% - modest capital efficiency.

Contextual notes:

• The 29.49% YoY drop in Q3 net profit can materially affect short-term investor sentiment despite an 18.00% operating margin that suggests underlying business strength.
• The spread between operating margin (18.00%) and net margin (7.48%) indicates meaningful deductions from operating profit - taxes, interest, minority interests, or non-operating items should be monitored.
• ROE of 9.01% and ROIC of 5.64% suggest returns are positive but modest; compare these to industry peers and the company's cost of capital for a fuller assessment.

For ownership trends and investor interest that may influence future capital allocation and profitability outlook, see: Exploring Beijing Tongrentang Co., Ltd Investor Profile: Who's Buying and Why?

Beijing Tongrentang Co., Ltd (600085.SS) - Debt vs. Equity Structure

• Cash and equivalents: CNY 11.4 billion vs. total debt: CNY 3.1 billion - net cash position.
• Debt-to-equity ratio: 0.19 - conservative leverage relative to equity.
• Interest coverage ratio: 17.15 - earnings cover interest expense by a wide margin.
• Short-term assets: CNY 24.5 billion vs. short-term liabilities: CNY 7.1 billion - strong short-term liquidity.
• Long-term assets: CNY 24.5 billion vs. long-term liabilities: CNY 3.3 billion - solid long-term solvency.
• Operating cash flow coverage of debt: 93.7% - near-full coverage of debt by operating cash flow.

Beijing Tongrentang Co., Ltd (600085.SS) - Liquidity and Solvency

Beijing Tongrentang's liquidity and solvency profile points to a conservative balance-sheet posture with strong short-term coverage, healthy operational cash generation, and comfortable capacity to service debt.

• Current ratio: 3.45 - more than adequate short-term asset coverage of liabilities.
• Quick ratio: 1.82 - sufficient liquid assets to meet immediate obligations without relying on inventory sales.
• Interest coverage ratio: 17.15 - robust ability to meet interest expenses from operating income.

The combination of a high current ratio and a quick ratio above 1.5 signals that short-term obligations are well covered by current and liquid assets. Strong net income of CNY 1.35 billion (TTM) and positive operating cash flow (CNY 761 million TTM) underpin ongoing solvency and operational resilience. Notably, free cash flow of CNY 1.1 billion provides discretionary capacity for capital allocation, dividends, or debt reduction.

• Operational cash generation (CNY 761m) vs. interest expense coverage (17.15x) suggests low refinancing risk in the near term.
• High current ratio (3.45) reduces short-term liquidity stress even under moderate revenue pressure.
• Free cash flow (CNY 1.1bn) offers flexibility for strategic uses without weakening liquidity ratios materially.

For additional context on ownership, investor interest, and what's driving demand for the stock, see: Exploring Beijing Tongrentang Co., Ltd Investor Profile: Who's Buying and Why?

Beijing Tongrentang Co., Ltd (600085.SS) - Valuation Analysis

Current market multiples for Beijing Tongrentang Co., Ltd (600085.SS) indicate how investors are pricing its earnings, book value, revenue and cash flows relative to peers and historical ranges. Key valuation metrics are summarized below and followed by targeted observations.

• Trailing twelve months (TTM) P/E: 32.02 - the market pays 32.02 times last 12 months' earnings.
• Forward P/E: 25.08 - implies expected earnings growth priced in by the market.
• P/B: 3.57 - market values the company at 3.57x its book value.
• EV/Revenue: 2.70 - enterprise value equals 2.70 times annual revenue.
• EV/EBITDA: 16.81 - indicates the enterprise value relative to operating cash earnings.
• EV/FCF: 19.30 - shows the valuation multiple on free cash flow generation.

Investor-focused takeaways:

• Premium valuation multiples (P/E, P/B) point to investor confidence in brand moat and earnings resilience.
• The gap between TTM P/E (32.02) and forward P/E (25.08) signals expected earnings recovery or margin expansion priced into the stock.
• EV/EBITDA at 16.81 and EV/FCF at 19.30 imply limited upside from multiple compression absent earnings or cash-flow improvement.
• EV/Revenue of 2.70 offers a quick cross-check versus peers for revenue quality and growth expectations.

For context on shareholder composition, recent flows and strategic investors, see: Exploring Beijing Tongrentang Co., Ltd Investor Profile: Who's Buying and Why?

Beijing Tongrentang Co., Ltd (600085.SS) - Risk Factors

• Revenue pressure: Q3 2025 revenue declined 12.76% year-over-year, signaling weakness in market demand, channel execution, or product mix.
• Profitability squeeze: Net profit fell 29.49% in Q3 2025 versus Q3 2024, implying margin compression and/or rising costs that management needs to address.
• Margin erosion: Reported declines in gross margin and operating income in Q3 2025 reduce the company's ability to absorb shocks and finance growth internally.
• Capital structure limits: A conservative debt-to-equity ratio of 0.19 indicates low financial leverage - while this limits solvency risk, it also constrains opportunities for accretive debt-funded expansion.
• Concentration risk: Heavy reliance on traditional Chinese medicine (TCM) product lines exposes the company to regulatory, safety, and reimbursement changes specific to TCM.
• Competitive risk: The pharmaceutical and wellness markets are increasingly competitive; rivals and new entrants may pressure pricing, distribution, and market share.

• Regulatory risk specifics: Potential regulatory tightening on TCM ingredients, manufacturing standards, advertising, and cross-border sales could raise compliance costs or limit certain product lines.
• Cost and pricing risk: The larger decline in net profit versus revenue (-29.49% vs -12.76%) suggests either rising input/operating costs, increased promotional spend, or pricing pressure eroding margins.
• Operational leverage: Declines in gross margin and operating income indicate weaker operational leverage; a rebound in sales may be required before profitability normalizes.
• Strategic flexibility: With D/E of 0.19 the company can borrow, but current conservative structure suggests management preference for lower financial risk - this might slow rapid expansion or M&A activity unless policy shifts.
• Market competition: Generic drug makers, modern TCM brands, and integrated healthcare players could capture share and compress Tongrentang's traditional channels and pricing power.

Beijing Tongrentang Co., Ltd (600085.SS) - Growth Opportunities

• Acquisition impact: A minority stake in a biotechnology firm (May 2023) focused on herbal medicine R&D is expected to contribute an estimated CNY 200 million to revenue over the next five years (≈CNY 40 million/year on average), strengthening the product pipeline and margins.
• Revenue trajectory: Analysts project a 12% CAGR for 2024-2026, lifting annual revenue from an implied 2023 baseline of ~CNY 2.14 billion to roughly CNY 3.00 billion by end-2026.
• Digital transformation: The company's push into online channels targets online sales representing up to 30% of total revenue by 2025, increasing reach and lowering distribution costs.
• Brand and R&D: Strong brand recognition in traditional Chinese medicine, together with ongoing R&D investment, underpins new product introductions and premium pricing potential.
• Partnerships and distribution: Strategic collaborations are expected to open new distribution channels and customer segments, accelerating adoption of new SKUs and online offerings.

• Key levers to watch: execution of the digital sales rollout, speed of R&D commercialization (from the biotech partner), and success of partnerships in new channels.
• Risks tied to execution: online channel conversion, regulatory changes for TCM products, and the pace at which new biotech-derived SKUs achieve market acceptance.